Biologics for Reducing Cardiovascular Risk in Psoriasis Patients

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


Psoriasis is a chronic inflammatory skin disease with a high prevalence of cardiovascular disease (CVD), obesity, dyslipidemia, hypertension, diabetes mellitus, and metabolic syndrome. Among them, CVD is the most common cause of morbidity and mortality in psoriasis patients. Since CVD is associated with considerable morbidity and mortality, primary care clinicians are increasingly committed to reducing the risk of CVD in patients with psoriasis. Biologics targeting TNF-α, IL-12/23, and IL-17 are systemic therapies that can dramatically improve the condition of psoriasis. Recent studies have reported that these inflammatory cytokine signals may promote atherosclerosis, suggesting that biologics might be effective for improving psoriasis as well as reducing the risk of CVD. Here, we reviewed cardiovascular risk in psoriasis patients, the association between psoriatic inflammation and atherosclerosis, and the efficacy of biologics for reducing the risk of cardiovascular diseases.

Original languageEnglish
Article number1162
JournalJournal of Clinical Medicine
Issue number3
Publication statusPublished - 2023 Feb


  • biologics
  • cardiovascular disease
  • psoriasis
  • systemic therapy


Dive into the research topics of 'Biologics for Reducing Cardiovascular Risk in Psoriasis Patients'. Together they form a unique fingerprint.

Cite this